Bone Marrow Transplant APP/PA — Flexible 5-Day Schedule

Franciscan Alliance, Inc.; Indianapolis (IN); Presencial; USD 110 000 - 140 000; Tempo integral

Vantagens oferecidas por esta oferta de emprego

Competitive compensation

Paid Time Off

Full benefits package

Retirement options (403(b), 457(b), 4

Disability Insurance

Resumo da oferta

Franciscan Health Indianapolis Campus is seeking an Advanced Practice Provider to support Indiana Blood & Marrow Transplantation (IBMT) at the Franciscan Cancer Center in Indianapolis, IN. The APP will join a collaborative team of three physicians and two APPs, assisting in both inpatient and outpatient BMT services.

The program performs allogeneic and autologous transplants with cellular therapies for hematologic malignancies, and includes an on-site apheresis unit and robust clinic trial

Qualificações

• Bone Marrow Transplant, Hematology and/or Oncology experience preferred, but not required.
• Ideal candidate thrives in a fast-paced environment and is team oriented.
• Candidate should develop exemplary professional relationships with patients and the community.

Responsabilidades

• Inpatient and outpatient responsibilities as part of the BMT team.
• Coordinate and deliver high-quality patient care with physicians.
• Offer bone marrow aspiration/biopsy skills; training provided if needed.
• Provide coverage in BMT inpatient and outpatient services on a rotating basis every two weeks.
• Support an established team of three physicians and two APPs.

Conhecimentos

BMT experience

Team oriented

Collaborative care

Formação académica

Master’s degree

PA-C certification or NP certification

Descrição da oferta de emprego

Franciscan Health Indianapolis Campus is seeking an Advanced Practice Provider to support Indiana Blood & Marrow Transplantation (IBMT) at the Franciscan Cancer Center in Indianapolis, IN. The APP will join a collaborative team of three physicians and two APPs, assisting in both inpatient and outpatient BMT services.

The program performs allogeneic and autologous transplants with cellular therapies for hematologic malignancies, and includes an on-site apheresis unit and robust clinic trial